Global Claudin 18.2 Targeted Therapy Market Report 2025

Item added to cart!

Report Price : $4490.00

Pages :

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF

Purchase This Report

Claudin 18.2 Targeted Therapy Global Market Report 2025

Name: Claudin 18.2 Targeted Therapy Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Therapy Type (Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types); By Indication (Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications); By Route Of Administration (Intravenous, Oral, Other Route Of Administrations); By End-User (Hospitals, Other End-Users); Subsegments:; By Monoclonal Antibodies (Chimeric Monoclonal Antibodies); By Bispecific Antibodies (Igg-Like Bispecific Antibodies); By Antibody-Drug Conjugates (Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates); By Other Therapy Types (Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Claudin 18.2 Targeted Therapy Market Overview

• Claudin 18.2 Targeted Therapy market size has reached to $1.29 billion in 2024

• Expected to grow to $3.73 billion in 2029 at a compound annual growth rate (CAGR) of 23.6%

• Growth Driver: Rising Gastrointestinal Cancer Incidence Driving The Market Growth Due To Increasing Prevalence And Unhealthy Diets

• Market Trend: Prominent Companies Pioneering Targeted Oncology Solutions

• Asia-Pacific was the largest region in 2024.

What Is Covered Under Claudin 18.2 Targeted Therapy Market?

Claudin 18.2 targeted therapy is an advanced precision cancer treatment designed to specifically target the Claudin 18.2 protein, abnormally overexpressed on the surface of certain tumor cells. This therapy selectively attacks cancer cells, improving treatment efficacy and reducing damage to healthy tissues.

The main therapy types of claudin 18.2 targeted therapy are Monoclonal Antibodies, bispecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are lab-made molecules designed to attach to specific proteins on cancer cells, helping the immune system target and destroy them. These therapies are mainly indicated for gastric cancer, pancreatic cancer, esophageal cancer, and others, and are administered via intravenous, oral, and other routes. The therapies are primarily used by end-users, including hospitals, oncology centers, research institutes, and others.

Claudin 18.2 Targeted Therapy Market Size and growth rate 2025 to 2029: Graph

What Is The Claudin 18.2 Targeted Therapy Market Size 2025 And Growth Rate?

What Is The Claudin 18.2 Targeted Therapy Market Growth Forecast?

The claudin 18.2 targeted therapy market size is expected to see exponential growth in the next few years. It will grow to $3.73 billion in 2029 at a compound annual growth rate (CAGR) of 23.6%. The growth in the forecast period can be attributed to rising approval of cldn18.2-targeted therapies, increasing prevalence of gastric and gastroesophageal junction (gej) cancers, expanding pipeline of cldn18.2-directed therapies, growing interest from pharmaceutical companies, and rising adoption of personalized medicine. Major trends in the forecast period include technological advancements in monoclonal antibody development, innovations in bispecific antibody therapies, developments in antibody-drug conjugates, investment in biomarker discovery and validation, and research and development in combination therapies.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How the Claudin 18.2 Targeted Therapy Market Segmented?

1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types

2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications

3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies

3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates

4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors

What Is Driving The Claudin 18.2 Targeted Therapy Market? Rising Gastrointestinal Cancer Incidence Driving The Market Growth Due To Increasing Prevalence And Unhealthy Diets

The rising incidence of gastrointestinal cancers is expected to propel the growth of the claudin 18.2 targeted therapy market going forward. Gastrointestinal (GI) cancers refer to malignant tumors that develop in any part of the digestive tract, from the esophagus to the rectum. The rise in gastrointestinal cancers is largely due to unhealthy diets rich in processed foods and low in fiber, promoting gut inflammation and increasing cancer risk. Claudin 18.2 targeted therapy helps treat gastrointestinal cancers by selectively targeting the Claudin 18.2 protein, overexpressed on cancer cells, enabling drugs or antibodies to kill cancer cells while sparing healthy tissue and improving treatment effectiveness. For instance, in July 2025, according to the National Library of Medicine, a US-based federal government, in 2022, the five gastrointestinal (GI) cancers accounted for 4,783,391 new cases and 3,235,719 deaths, representing 23.9% of all new cancer cases and 33.2% of all cancer-related deaths globally. Therefore, the rising incidence of gastrointestinal cancers is driving the growth of the Claudin 18.2 targeted therapy industry.

Who Are The Major Players In The Global Claudin 18.2 Targeted Therapy Market?

Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.

What Are The Key Trends Of The Global Claudin 18.2 Targeted Therapy Market? Prominent Companies Pioneering Targeted Oncology Solutions

Major companies operating in the claudin 18.2 targeted therapy market are focusing on developing innovative solutions, such as monoclonal antibodies, to specifically target claudin 18.2-expressing cancer cells and enhance treatment outcomes. A monoclonal antibody is a laboratory-engineered protein designed to bind precisely to a single target, such as a protein on the surface of cancer cells, aiding the immune system in recognizing and attacking these cells. For instance, in March 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, obtained approval from Japan's Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab) for the treatment of patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively binds to the CLDN18.2 protein on tumor cells, activating the immune system to destroy cancer cells. Clinical trials showed it significantly improves progression-free and overall survival when combined with chemotherapy compared to chemotherapy alone. This innovative therapy provides a new, effective option for patients with HER2-negative, CLDN18.2-positive tumors, fulfilling an unmet need in aggressive gastric cancer.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Claudin 18.2 Targeted Therapy Market? Phastar CRO Acquires S-Cubed Aps To Enhance Clinical Trial Data Visualization Capabilities

In February 2024, AstraZeneca plc, a UK-based pharmaceutical industry company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to accelerate its cell therapy strategy by expanding its pipeline with Gracell's innovative CAR-T therapies targeting blood cancers and autoimmune diseases, leveraging Gracell’s FasTCAR platform to improve treatment efficacy and manufacturing speed. Gracell Biotechnologies Inc. is a China-based clinical-stage biopharmaceutical company that offers claudin 18.2 targeted therapy.

What Is The Regional Outlook For The Global Claudin 18.2 Targeted Therapy Market?

Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2024. The regions covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Claudin 18.2 Targeted Therapy Market?

The claudin 18.2 targeted therapy market consists of sales of zolbetuximab, CMG901, and bispecific antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Claudin 18.2 Targeted Therapy Industry?

The claudin 18.2 targeted therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the claudin 18.2 targeted therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

1. Executive Summary

2. Claudin 18.2 Targeted Therapy Market Characteristics

3. Claudin 18.2 Targeted Therapy Market Trends And Strategies

4. Claudin 18.2 Targeted Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Claudin 18.2 Targeted Therapy Growth Analysis And Strategic Analysis Framework

5.1. Global Claudin 18.2 Targeted Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Claudin 18.2 Targeted Therapy Market Growth Rate Analysis

5.4. Global Claudin 18.2 Targeted Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Claudin 18.2 Targeted Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Claudin 18.2 Targeted Therapy Total Addressable Market (TAM)

6. Claudin 18.2 Targeted Therapy Market Segmentation

6.1. Global Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monoclonal Antibodies

Bispecific Antibodies

Antibody-Drug Conjugates

Other Therapy Types

6.2. Global Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Gastric Cancer

Pancreatic Cancer

Esophageal Cancer

Other Indications

6.3. Global Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous

Oral

Other Route Of Administrations

6.4. Global Claudin 18.2 Targeted Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Oncology Centers

Research Institutes

Other End-Users

6.5. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Chimeric Monoclonal Antibodies

Humanized Monoclonal Antibodies

Fully Human Monoclonal Antibodies

6.6. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Igg-Like Bispecific Antibodies

Non-Igg-Like Bispecific Antibodies

6.7. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Antibody-Drug Conjugates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Microtubule Inhibitor-Based Antibody-Drug Conjugates

Dna Damaging Agent-Based Antibody-Drug Conjugates

Topoisomerase Inhibitor-Based Antibody-Drug Conjugates

6.8. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Car-T Cell Therapy

Vaccines

Small Molecule Inhibitors

7. Claudin 18.2 Targeted Therapy Market Regional And Country Analysis

7.1. Global Claudin 18.2 Targeted Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Claudin 18.2 Targeted Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Claudin 18.2 Targeted Therapy Market

8.1. Asia-Pacific Claudin 18.2 Targeted Therapy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Claudin 18.2 Targeted Therapy Market

9.1. China Claudin 18.2 Targeted Therapy Market Overview

9.2. China Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Claudin 18.2 Targeted Therapy Market

10.1. India Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Claudin 18.2 Targeted Therapy Market

11.1. Japan Claudin 18.2 Targeted Therapy Market Overview

11.2. Japan Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Claudin 18.2 Targeted Therapy Market

12.1. Australia Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Claudin 18.2 Targeted Therapy Market

13.1. Indonesia Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Claudin 18.2 Targeted Therapy Market

14.1. South Korea Claudin 18.2 Targeted Therapy Market Overview

14.2. South Korea Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Claudin 18.2 Targeted Therapy Market

15.1. Western Europe Claudin 18.2 Targeted Therapy Market Overview

15.2. Western Europe Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Claudin 18.2 Targeted Therapy Market

16.1. UK Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Claudin 18.2 Targeted Therapy Market

17.1. Germany Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Claudin 18.2 Targeted Therapy Market

18.1. France Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Claudin 18.2 Targeted Therapy Market

19.1. Italy Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Claudin 18.2 Targeted Therapy Market

20.1. Spain Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Claudin 18.2 Targeted Therapy Market

21.1. Eastern Europe Claudin 18.2 Targeted Therapy Market Overview

21.2. Eastern Europe Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Claudin 18.2 Targeted Therapy Market

22.1. Russia Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Claudin 18.2 Targeted Therapy Market

23.1. North America Claudin 18.2 Targeted Therapy Market Overview

23.2. North America Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Claudin 18.2 Targeted Therapy Market

24.1. USA Claudin 18.2 Targeted Therapy Market Overview

24.2. USA Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Claudin 18.2 Targeted Therapy Market

25.1. Canada Claudin 18.2 Targeted Therapy Market Overview

25.2. Canada Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Claudin 18.2 Targeted Therapy Market

26.1. South America Claudin 18.2 Targeted Therapy Market Overview

26.2. South America Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Claudin 18.2 Targeted Therapy Market

27.1. Brazil Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Claudin 18.2 Targeted Therapy Market

28.1. Middle East Claudin 18.2 Targeted Therapy Market Overview

28.2. Middle East Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Claudin 18.2 Targeted Therapy Market

29.1. Africa Claudin 18.2 Targeted Therapy Market Overview

29.2. Africa Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Claudin 18.2 Targeted Therapy Market Competitive Landscape And Company Profiles

30.1. Claudin 18.2 Targeted Therapy Market Competitive Landscape

30.2. Claudin 18.2 Targeted Therapy Market Company Profiles

30.2.1. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Jiangsu Hengrui Medicine Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Shanghai Henlius Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Claudin 18.2 Targeted Therapy Market Other Major And Innovative Companies

31.1. Legend Biotech Corporation

31.2. Zai Lab Limited

31.3. Harbour Biomed Ltd.

31.4. CARsgen Therapeutics Holdings Limited

31.5. Genor Biopharma Co. Ltd.

31.6. Phanes Therapeutics Inc.

31.7. Suzhou Zelgen Biopharmaceuticals Co. Ltd.

31.8. Triumvira Immunologics Inc.

31.9. SOTIO Biotech a.s.

31.10. Leap Therapeutics

31.11. Allogene Therapeutics

31.12. AskGene Pharma Inc.

31.13. Elpiscience Biopharmaceutical Co. Ltd.

31.14. I-Mab Biopharma Co. Ltd.

31.15. Antegene Biopharma Co. Ltd.

32. Global Claudin 18.2 Targeted Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Claudin 18.2 Targeted Therapy Market

34. Recent Developments In The Claudin 18.2 Targeted Therapy Market

35. Claudin 18.2 Targeted Therapy Market High Potential Countries, Segments and Strategies

35.1 Claudin 18.2 Targeted Therapy Market In 2029 - Countries Offering Most New Opportunities

35.2 Claudin 18.2 Targeted Therapy Market In 2029 - Segments Offering Most New Opportunities

35.3 Claudin 18.2 Targeted Therapy Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Claudin 18.2 Targeted Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Antibody-Drug Conjugates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Claudin 18.2 Targeted Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Claudin 18.2 Targeted Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Bristol Myers Squibb Company Financial Performance

Table 80: Amgen Inc. Financial Performance

Table 81: Astellas Pharma Inc. Financial Performance

Table 82: Jiangsu Hengrui Medicine Co. Ltd. Financial Performance

Table 83: Shanghai Henlius Biotech Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Claudin 18.2 Targeted Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Antibody-Drug Conjugates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Claudin 18.2 Targeted Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Claudin 18.2 Targeted Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Bristol Myers Squibb Company Financial Performance

Figure 80: Amgen Inc. Financial Performance

Figure 81: Astellas Pharma Inc. Financial Performance

Figure 82: Jiangsu Hengrui Medicine Co. Ltd. Financial Performance

Figure 83: Shanghai Henlius Biotech Inc. Financial Performance

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Forecast 2025–2034: Trends Reshaping Demand, Investment, and Innovation

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Projected to Reach $47.74 Billion by 2029 at a CAGR of 30.7%

$8.21 Billion Forecast for Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market by 2029, Backed by Demand and Innovation

Fentanyl Market Forecast Reaching $22.03 Billion by 2029 at 6.5% CAGR

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

COVID-19 Current Therapy Global Market Report 2025 – By Drug Type (Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs, Others),...

Next-Generation Antibody Therapeutics Global Market Report 2025 – By Types Of Antibodies (Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types), By Therapeutic Area ...

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025 – By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degenerat...

Blood Cancer Drugs Global Market Report 2025 – By Blood Cancer Type (Leukemia, Lymphoma), By Drugs (Rituxan/Mabthera (Rituximab), Gleevec/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotin...

Oligonucleotide Therapy Global Market Report 2025 – By Type (Antisense Oligonucleotide, Aptamer, Other Types), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney D...

Clopidogrel Global Market Report 2025 – By Type (25Mg, 75Mg, 300Mg), By Sales Channel (Direct Sale, Indirect Sale), By Application (Hospitals, Private Clinics, Retail Pharmacies, Online Pharmacies, Other Applications), B...

Neoantigen Targeted Therapies Global Market Report 2025 – By Type (Monotherapy, Combination Therapy), By Immunotherapy Type (DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies...

Frequently Asked Questions

What is the definition of the Claudin 18.2 Targeted Therapy market?

How will the Claudin 18.2 Targeted Therapy market drivers and restraints affect the market dynamics? What forces will shape the Claudin 18.2 Targeted Therapy industry going forward?

The market major growth driver - Rising Gastrointestinal Cancer Incidence Driving The Market Growth Due To Increasing Prevalence And Unhealthy Diets. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Claudin 18.2 Targeted Therapy market?

The claudin 18.2 targeted therapy market size has grown exponentially in recent years. It will grow from $1.29 billion in 2024 to $1.60 billion in 2025 at a compound annual growth rate (CAGR) of 23.9%. The growth in the historic period can be attributed to increasing research and development activities, increasing government and institutional support, rising incidence of pancreatic cancer, increasing healthcare investments in oncology, and expanding global access to targeted therapies. The claudin 18.2 targeted therapy market size is expected to see exponential growth in the next few years. It will grow to $3.73 billion in 2029 at a compound annual growth rate (CAGR) of 23.6%. The growth in the forecast period can be attributed to rising approval of cldn18.2-targeted therapies, increasing prevalence of gastric and gastroesophageal junction (gej) cancers, expanding pipeline of cldn18.2-directed therapies, growing interest from pharmaceutical companies, and rising adoption of personalized medicine. Major trends in the forecast period include technological advancements in monoclonal antibody development, innovations in bispecific antibody therapies, developments in antibody-drug conjugates, investment in biomarker discovery and validation, and research and development in combination therapies. For further insights on this market, request a sample here

How is the Claudin 18.2 Targeted Therapy market segmented?

The claudin 18.2 targeted therapy market covered in this report is segmented as
1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types
2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications
3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations
4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies
3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors For further insights on this market, request a sample here

Which region has the largest share of the Claudin 18.2 Targeted Therapy market? What are the other regions covered in the report?

Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2024. The regions covered in claudin 18.2 targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. For further insights on this market, request a sample here.

Who are the major players in the Claudin 18.2 Targeted Therapy market?

What are the key trends in the Claudin 18.2 Targeted Therapy market?

Major trends in this market include Prominent Companies Pioneering Targeted Oncology Solutions For further insights on this market, request a sample here.